Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nevro Corp (NVRO)

Nevro Corp (NVRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 499,744
  • Shares Outstanding, K 36,398
  • Annual Sales, $ 425,170 K
  • Annual Income, $ -92,210 K
  • 60-Month Beta 0.91
  • Price/Sales 1.19
  • Price/Cash Flow N/A
  • Price/Book 1.72
Trade NVRO with:

Options Overview Details

View History
  • Implied Volatility 65.33% ( +4.99%)
  • Historical Volatility 50.61%
  • IV Percentile 58%
  • IV Rank 47.04%
  • IV High 111.48% on 11/20/23
  • IV Low 24.33% on 06/01/23
  • Put/Call Vol Ratio 0.08
  • Today's Volume 42
  • Volume Avg (30-Day) 256
  • Put/Call OI Ratio 10.06
  • Today's Open Interest 10,967
  • Open Int (30-Day) 11,048

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.02
  • Number of Estimates 8
  • High Estimate -0.77
  • Low Estimate -1.16
  • Prior Year -0.98
  • Growth Rate Est. (year over year) -4.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.36 +5.46%
on 03/05/24
17.53 -19.62%
on 02/20/24
-3.23 (-18.65%)
since 02/16/24
3-Month
13.36 +5.46%
on 03/05/24
22.52 -37.45%
on 12/28/23
-7.71 (-35.37%)
since 12/18/23
52-Week
13.36 +5.46%
on 03/05/24
39.67 -64.49%
on 04/19/23
-16.40 (-53.79%)
since 03/17/23

Most Recent Stories

More News
Why Nevro Stock Lagged the Market on Thursday

Despite convincing beats on its latest set of quarterly figures, the market wasn't all that impressed with the company's latest developments.

NVRO : 14.09 (+2.62%)
Nevro: Q4 Earnings Snapshot

Nevro: Q4 Earnings Snapshot

NVRO : 14.09 (+2.62%)
Nevro: Q3 Earnings Snapshot

Nevro: Q3 Earnings Snapshot

NVRO : 14.09 (+2.62%)
Nevro to Report Third Quarter 2023 Financial Results

/PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of...

NVRO : 14.09 (+2.62%)
New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy

/PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of...

NVRO : 14.09 (+2.62%)
Nevro Announces Participation in Upcoming Investor Conferences

/PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

NVRO : 14.09 (+2.62%)
New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

/PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain,...

NVRO : 14.09 (+2.62%)
Why Shares of Nevro Are Down Wednesday

The medical device maker saw increased revenue, but earnings lagged estimates.

NVRO : 14.09 (+2.62%)
Nevro: Q2 Earnings Snapshot

Nevro: Q2 Earnings Snapshot

NVRO : 14.09 (+2.62%)
Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance

/PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of...

NVRO : 14.09 (+2.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nevro Corp. is a medical device company which engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain, primarily in the leg. The company is known for developing and commercializing the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation...

See More

Key Turning Points

3rd Resistance Point 15.05
2nd Resistance Point 14.64
1st Resistance Point 14.37
Last Price 14.09
1st Support Level 13.69
2nd Support Level 13.28
3rd Support Level 13.01

See More

52-Week High 39.67
Fibonacci 61.8% 29.62
Fibonacci 50% 26.52
Fibonacci 38.2% 23.41
Last Price 14.09
52-Week Low 13.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar